CMS Urine Culture Coverage Policy Updated for 2026 — What Billing Teams Need to Know

CMS has modified National Coverage Determination (NCD) 25, governing bacterial urine culture testing, with an effective date of March 12, 2026. This update refines the indications, limitations, and coverage criteria for urine culture procedures billed to Medicare — directly affecting labs, urology practices, primary care, and any facility ordering urine cultures as part of UTI workup or surgical pre-clearance. If your billing team handles diagnostic laboratory claims for Medicare patients, this policy deserves a close look before the effective date.

What NCD 25 Covers — CMS Bacterial Urine Culture Medical Necessity Criteria

Under NCD 25, a bacterial urine culture is defined as a laboratory procedure performed on a urine specimen to establish the probable etiology of a presumed urinary tract infection. The procedure includes aerobic agar-based isolation of bacteria or other cultivable organisms, quantification based on morphologic criteria, and — when clinically indicated — additional identification and susceptibility testing on significant isolates. Critically, that last step can be triggered through clearly documented and communicated laboratory protocols, not just a direct per-specimen physician order.

CMS outlines six covered indications for bacterial urine culture under NCD 25. Documentation in the medical record must tie the order to one of these specific clinical scenarios to support medical necessity:

Indication 1 — Abnormal Urinalysis
An antecedent urinalysis with findings suggesting UTI — such as hematuria, pyuria, bacteriuria, positive leukocyte esterase or nitrite, positive Gram's stain, or a positive bacteriuria screen via non-culture technique — supports coverage. Importantly, the policy notes that a prior urinalysis is not strictly required if clinical presentation is highly suggestive and the clinician documents accordingly.

Indication 2 — Clinical Signs and Symptoms of UTI
Classic lower UTI symptoms (urgency, frequency, nocturia, dysuria, discharge, incontinence) and upper UTI symptoms (fever, chills, costovertebral or pelvic pain) qualify. CMS explicitly calls out that elderly, immunocompromised, and neurologically impaired patients may present atypically — with general debility, acute mental status changes, or declining functional status — and that documentation of these atypical presentations can support coverage.

Indication 3 — Urosepsis, Fever of Unknown Origin, or Systemic Infection Without Identified Source
When a patient is being evaluated for suspected urosepsis or a systemic infection with no confirmed source, urine culture is covered. Documentation should reflect the broader sepsis workup context and the absence of a known infectious source at the time of the order.

Indication 4 — Test-of-Cure in Complicated Infections
A post-treatment test-of-cure culture is generally not covered for uncomplicated UTIs. However, it is covered when the patient has a complicating structural or functional urinary abnormality — including calculi, foreign bodies, or ureteral/renal stents — or when there is clinical or laboratory evidence of treatment failure as described in Indications 1 and 2. Billing teams should flag this distinction carefully: routine post-treatment cultures on uncomplicated cases will not pass medical necessity review.

Indication 5 — Preoperative Evaluation for Major Genitourinary Procedures
Preoperative occult infection screening is covered in selected cases involving major manipulation of the genitourinary tract, including renal transplantation, kidney stone manipulation or removal, and transurethral surgery of the bladder or prostate. Documentation should reflect the specific procedure type and the rationale for pre-op culture in that context.

Indication 6 — Renal Transplant Recipients on Immunosuppressive Therapy
Urine culture to detect occult infection in immunosuppressed renal transplant recipients is a covered indication under this NCD. This is distinct from a symptomatic presentation — it supports surveillance-based ordering in this high-risk population.

CMS NCD 25 Billing Limitations — What Restricts Coverage

Beyond the six indications, NCD 25 includes specific billing limitations that directly govern how codes may be reported:

• CPT 87086 (urine culture, bacterial; quantitative colony count) may be used one time per encounter. Multiple units on a single claim date will not be supported.
• CPT 87088 (urine culture, bacterial; with isolation and presumptive identification of each isolate) has no colony count restrictions on coverage, as counts may be highly variable based on antecedent therapy, collection time, or degree of hydration. Do not allow a lab's internal colony count threshold to drive a coverage denial argument against this code.
• CPT 87088, 87184 (disk diffusion susceptibility testing), and 87186 (susceptibility testing, microdilution or agar dilution; each antibiotic) may be billed multiple times — independently of, or in association with, 87086 — because urinary tract infections may be polymicrobial.
• Testing for asymptomatic bacteriuria is addressed but the policy summary was truncated at that point. Billing teams should access the full policy text at https://app.payerpolicy.org/p/cms/25-v1 to confirm coverage status for asymptomatic bacteriuria scenarios before billing.

Affected Codes

The policy data provided does not include a finalized code list in the structured code tables for this version of NCD 25. However, based on direct references within the policy's limitations text, the following CPT codes are explicitly cited:

Important: These codes are referenced directly in the NCD 25 limitations language. Confirm current RVU and fee schedule applicability in the 2026 Medicare Physician Fee Schedule. No ICD-10-CM codes were listed in the policy data provided for this version.

What Your Billing Team Should Do